People · Operator

Carol D. Karp

Named in public records as an officer, director or promoter · active 2018–2018 · Biotechnology

1
Companies
1
Filings
$50.0M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Prothena Corp plcBiotechnologySeries C$50.0M$2.0B2018
Operator network

Carol D. Karp at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Karin L. Walker · 2 companies · 1 sharedKarin L. WalkerAnders O. Harfstrand, M.D., Ph.D. · 1 companies · 1 sharedAnders O. Harfstr…Arthur W. Homan · 1 companies · 1 sharedArthur W. HomanChristopher S. Henney, Ph.D., D.Sc. · 1 companies · 1 sharedChristopher S. He…Dennis J. Selkoe · 1 companies · 1 sharedDennis J. SelkoeGene G. Kinney, Ph.D. · 1 companies · 1 sharedGene G. Kinney, P…Lars G. Eckman, M.D., Ph.D. · 1 companies · 1 sharedLars G. Eckman, M…Richard T. Collier · 1 companies · 1 sharedRichard T. CollierShane M. Cooke · 1 companies · 1 sharedShane M. CookeTara B. Nickerson, Ph.D. · 1 companies · 1 sharedTara B. Nickerson…Tran B. Nguyen · 1 companies · 1 sharedTran B. NguyenWagner M. Zago, Ph.D. · 1 companies · 1 sharedWagner M. Zago, P…Prothena Corp plc · $50.0M raisedProthena Corp plcCarol D. KarpCK
Carol D. Karp Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Carol D. Karp on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Karin L. Walker12
Richard T. Collier11
Tran B. Nguyen11
Arthur W. Homan11
Lars G. Eckman, M.D., Ph.D.11
Dennis J. Selkoe11
Tara B. Nickerson, Ph.D.11
Wagner M. Zago, Ph.D.11
Christopher S. Henney, Ph.D., D.Sc.11
Shane M. Cooke11
Anders O. Harfstrand, M.D., Ph.D.11
Gene G. Kinney, Ph.D.11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.